CA3248640A1 - METHODS OF TREATMENT FOR NEURO-INFLAMMATORY DISEASES - Google Patents
METHODS OF TREATMENT FOR NEURO-INFLAMMATORY DISEASESInfo
- Publication number
- CA3248640A1 CA3248640A1 CA3248640A CA3248640A CA3248640A1 CA 3248640 A1 CA3248640 A1 CA 3248640A1 CA 3248640 A CA3248640 A CA 3248640A CA 3248640 A CA3248640 A CA 3248640A CA 3248640 A1 CA3248640 A1 CA 3248640A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- mmol
- pharmaceutically acceptable
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338328P | 2022-05-04 | 2022-05-04 | |
| US63/338,328 | 2022-05-04 | ||
| US202263414111P | 2022-10-07 | 2022-10-07 | |
| US63/414,111 | 2022-10-07 | ||
| US202263424352P | 2022-11-10 | 2022-11-10 | |
| US63/424,352 | 2022-11-10 | ||
| US202363447432P | 2023-02-22 | 2023-02-22 | |
| US63/447,432 | 2023-02-22 | ||
| PCT/US2023/020832 WO2023215377A1 (en) | 2022-05-04 | 2023-05-03 | Methods of treating neuroinflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248640A1 true CA3248640A1 (en) | 2023-11-09 |
Family
ID=86693083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248640A Pending CA3248640A1 (en) | 2022-05-04 | 2023-05-03 | METHODS OF TREATMENT FOR NEURO-INFLAMMATORY DISEASES |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250275976A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518865A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515045A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250005230A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119156217A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023263997A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248640A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316281A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202406554A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215377A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025538382A (ja) * | 2022-11-18 | 2025-11-28 | アティラ・ファーマ・インコーポレイテッド | 炎症病態を治療する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO2004035587A1 (en) * | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US20140094413A1 (en) | 2012-04-02 | 2014-04-03 | Washington State University | Hepatocyte growth factor (hgf) mimics as therapeutic agents |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| AU2021371026A1 (en) * | 2020-11-02 | 2023-06-15 | LeonaBio, Inc. | Bicyclic compounds and uses thereof for the treatment of diseases |
| IL313039A (en) * | 2021-12-17 | 2024-07-01 | Athira Pharma Inc | Uses of bicyclic compounds for the treatment of diseases |
-
2023
- 2023-05-03 US US18/858,864 patent/US20250275976A1/en active Pending
- 2023-05-03 EP EP23728898.0A patent/EP4518865A1/en active Pending
- 2023-05-03 KR KR1020247037070A patent/KR20250005230A/ko active Pending
- 2023-05-03 TW TW112116504A patent/TW202406554A/zh unknown
- 2023-05-03 WO PCT/US2023/020832 patent/WO2023215377A1/en not_active Ceased
- 2023-05-03 CA CA3248640A patent/CA3248640A1/en active Pending
- 2023-05-03 JP JP2024564715A patent/JP2025515045A/ja active Pending
- 2023-05-03 AU AU2023263997A patent/AU2023263997A1/en active Pending
- 2023-05-03 CN CN202380037527.9A patent/CN119156217A/zh active Pending
- 2023-05-03 IL IL316281A patent/IL316281A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023263997A1 (en) | 2024-10-24 |
| IL316281A (en) | 2024-12-01 |
| US20250275976A1 (en) | 2025-09-04 |
| CN119156217A (zh) | 2024-12-17 |
| WO2023215377A1 (en) | 2023-11-09 |
| TW202406554A (zh) | 2024-02-16 |
| EP4518865A1 (en) | 2025-03-12 |
| KR20250005230A (ko) | 2025-01-09 |
| JP2025515045A (ja) | 2025-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107001378A (zh) | 吡咯并嘧啶化合物 | |
| TWI918751B (zh) | 用於治療疾病之雙環化合物及其用途 | |
| WO2023215377A1 (en) | Methods of treating neuroinflammatory conditions | |
| WO2023114456A1 (en) | Uses of bicyclic compounds for the treatment of diseases | |
| US20250161308A1 (en) | Methods of Treating Covid-Related Disorders | |
| EP4518866A1 (en) | Methods of treating fibrosis | |
| EA050745B1 (ru) | Применение бициклических соединений для лечения заболеваний | |
| CA3248537A1 (en) | METHODS OF TREATMENT FOR NEUROPATHIES | |
| US20260109690A1 (en) | Hdac6 inhibitors and method of their use | |
| EA049703B1 (ru) | Бициклические соединения и их применение для лечения заболеваний | |
| CN118382441A (zh) | 双环化合物用于治疗疾病的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241011 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241106 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241106 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250423 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260420 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260428 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260504 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |